DRUG
SHORT CANDIDATEMeanRevComposite
29.80
Technical
62.10
Fundamental
19.10
Rank
—
Price
79.49
Hurst
0.27
As of
Aug 26, 2026
Daily
Bright Minds Biosciences Inc.
HealthcareBiotechnologyBright Minds Biosciences is a biotechnology firm focused on developing treatments for serious neurological and psychiatric conditions. The company's pipeline includes experimental therapies targeting serotonin receptors for conditions such as epilepsy, developmental and epileptic encephalopathies, and Prader Willi Syndrome, with lead candidates currently in phase 1 and phase 2 clinical trials. Founded in 2017 and based in New York, the company collaborates with other organizations to support its clinical research programs.
Market cap
$542.3M
P/E (trailing)
—
P/E (forward)
-9.52
PEG ratio
—
Dividend yield
0.00%
Beta
0.23
52w range
47.23 – 123.75
Return on equity
-13.63%
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 54.98 (+0.4%) · range 48.25–95.99
Cycle position
27/ 100 cycle scoreENTRY ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 54 · MODERATE · exit proximity 0
Conviction
28/ 100 · maturity 0%
Buildup.333
EMA entry setup.4254
Fundamentals.2519
Volume profile
POC
75.44
Price vs POC
-27.1%
Overhead supply
88%
Runway
+9.5%
Value area 59.77–81.26 · 88% of 120d volume overhead · heavy supply
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -30.17% | -2.73% | mature |
| 40d | -31.24% | -2.73% | mature |